Navigation Links
Clavis Pharma Presented Preliminary Clinical Data on Elacyt at EHA

OSLO, Norway, 11 June 2007 - Clavis Pharma (OSE: CLAVIS) presented an update of data from its ongoing clinical Phase I/II study with ELACYT in hematologic cancers during a poster session at the Annual Meeting of the European Hematology Association (EHA) in Vienna. ELACYT is a novel cytotoxic agent in development for the treatment of hematologic cancers as well as for solid tumours. In this ongoing Phase I/II study Clavis Pharma reports that patients with hematologic malignancies have tolerated ELACYT well at doses up to 1150 mg/m²/day (2 hour infusion) and 675 mg/m²/day (continuous infusion). Initial results from this study were presented at AACR in April this year.

The phase I/II study is currently in its dose escalating phase with the aim to define the maximum tolerated dose, the optimal regimen and to characterize the safety profile of ELACYT given as a single agent in patients with hematologic malignancies. The second part of the study will evaluate the effect of ELACYT.

"The updated clinical results confirm the good safety profile seen with ELACYT so far" says Tom Pike, CEO of Clavis Pharma. "The progress of the study shows excellent recruitment in both continents high and we hope to be able to open the phase II part shortly."

The centres involved in this multicentre Phase I/II study are MD Anderson Cancer Centre, Houston, Texas, USA, Institute Paoli Calmettes, Marseille, France and Duke University Hospital, USA. A number of new sites have been recruited for the Phase II - efficacy part of the study. The Co-ordinating Investigator of the study is Professor Frank Giles, Chief, Division of Hematology and Medical Oncology, University of Texas Health Science Center at San Antonio

Contact: Tom Pike Chief Executive Officer Tel: + 47 915 19 652 / + 47 24 11 09 50 tom.pike@clavispharma.com www.clavispharma.com


'"/>




Related medicine technology :

1. Sygnis Pharma AG announces date for presentation of clinical results
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
6. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
7. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
8. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
9. Array BioPharma to Present at the C.E Unterbeg, Towbin Emerging Growth Conference
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... -- Global Cervical Dysplasia Market: Scope and Methodology ... market analyzes the current and future prospects of ... summary, including a market snapshot that provides overall ... research is a combination of primary and secondary ... research efforts along with information collected from telephonic ...
(Date:12/7/2016)... 2016  Palatin Technologies, Inc. ("Palatin") (NYSE MKT: ... previously disclosed underwritten public offering of units with ... sole book-running manager, Roth Capital Partners acted as ... co-manager for the offering. "This financing ... proceeds, allowing us to continue advancing bremelanotide for ...
(Date:12/7/2016)... NEW YORK , Dec. 7, 2016 /PRNewswire/ ... This report on pulmonary drugs studies the current ... globally. The stakeholders of this report include companies ... of various pulmonary/respiratory drugs and/or drug-device combinations as ... market. This report comprises an elaborate executive summary ...
Breaking Medicine Technology:
(Date:12/8/2016)... Fort Myers, FL (PRWEB) , ... December 08, 2016 , ... ... that serves business owners and families in and around the Cape Coral area, is ... the Harry Chapin Food Bank of Southwest Florida. , The Harry Chapin Food Bank ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... families and business owners in and around central Kansas, is joining the Youth ... youth in the region. , Headquartered in Wichita, Youth Horizons works to empower ...
(Date:12/7/2016)... ... December 07, 2016 , ... "Today, MHA ... most comprehensive mental health systems reform legislation in more than fifty years. We ... the commitment of our elected officials to improving mental health services and supports ...
(Date:12/7/2016)... ... 07, 2016 , ... Silhouette Instalift is a simple, minimally ... tightening the skin of the face to create more youthful features. While there ... little downtime, Silhouette Instalift is a novel, minimally invasive facial procedure that lifts ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... acquired Presence Technology, S.L. (“Presence”) for a purchase price of approximately $17.4 ... other considerations. Presence’s annual revenue is approximately $13.2 million. Headquartered in Barcelona, ...
Breaking Medicine News(10 mins):